Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Weiting Lian"'
Autor:
Ning WAN, Bing WANG, Ya GUO, Zijian HE, Chen YANG, Ning YANG, Liqing LU, Hongyi LIANG, Weibin XIAO, Dandan YANG, Zhuojia CHEN, Wenfeng FANG, Weiting LIANG
Publikováno v:
Chinese Journal of Lung Cancer, Vol 27, Iss 10, Pp 745-754 (2024)
Background and objective Pembrolizumab (PEM) has been shown to be effective in clinical trials for the treatment of advanced non-small cell lung cancer (NSCLC), but clinical trials were based on cohorts of patients selected on specific criteria, and
Externí odkaz:
https://doaj.org/article/f7e48e213b3349f69dc96ca4e441ba7e
Autor:
Yanmei Ju, Zhe Zhang, Mingliang Liu, Shutian Lin, Qiang Sun, Zewei Song, Weiting Liang, Xin Tong, Zhuye Jie, Haorong Lu, Kaiye Cai, Peishan Chen, Xin Jin, Wenwei Zhang, Xun Xu, Huanming Yang, Jian Wang, Yong Hou, Liang Xiao, Huijue Jia, Tao Zhang, Ruijin Guo
Publikováno v:
Genome Biology, Vol 25, Iss 1, Pp 1-24 (2024)
Abstract Background Respiratory diseases impose an immense health burden worldwide. Epidemiological studies have revealed extensive disparities in the incidence and severity of respiratory tract infections between men and women. It has been hypothesi
Externí odkaz:
https://doaj.org/article/8fee651512cc4baa93064cd284c28464
Publikováno v:
2022 13th International Conference on Network of the Future (NoF).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5f53684a301534ee54479c235657aef4
https://doi.org/10.1109/nof55974.2022.9942601
https://doi.org/10.1109/nof55974.2022.9942601
Autor:
Weiting Liang, Zhijun Guo, Yunhui Zhang, Ning Yang, Chenchen Guo, Tao Liu, Hongbing Huang, Zhuojia Chen
Publikováno v:
Case Reports in Oncology, Vol 17, Iss 1, Pp 361-369 (2024)
Introduction: Cadonilimab (AK104) is an innovative human programmed cell death-1 (PD-1)/cytotoxic T lymphocyte antigen-4 (CTLA-4) bispecific antibody. Compared with the combination therapy of PD-1 and CTLA-4 blockers, less cellular toxicity of cadoni
Externí odkaz:
https://doaj.org/article/5f2dba4a7ba04cc9807b3e8d48701a60
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Background: Malignant melanoma is a highly aggressive cancer that spreads and metastasizes quickly. In recent years, the antiangiogenic drug bevacizumab has been trialed to treat malignant melanoma. We conducted the first meta-analysis to examine the
Externí odkaz:
https://doaj.org/article/ed33ffac0a064f368290ef3b2a249249
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundAfatinib is a potent, irreversible second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor which has demonstrated efficacy in advanced non-small cell lung cancer (NSCLC) patients harboring either common or uncomm
Externí odkaz:
https://doaj.org/article/c1b60c683cf544b79e7fb36c292fcdb6
Autor:
Peng Deng, Zining Wang, Jinghong Chen, Shini Liu, Xiaosai Yao, Shaoyan Liu, Lizhen Liu, Zhaoliang Yu, Yulin Huang, Zhongtang Xiong, Rong Xiao, Jiuping Gao, Weiting Liang, Jieping Chen, Hui Liu, Jing Han Hong, Jason Yongsheng Chan, Peiyong Guan, Jianfeng Chen, Yali Wang, Jiaxin Yin, Jundong Li, Min Zheng, Chao Zhang, Penghui Zhou, Tiebang Kang, Bin Tean Teh, Qiang Yu, Zhixiang Zuo, Qingping Jiang, Jihong Liu, Ying Xiong, Xiaojun Xia, Jing Tan
Publikováno v:
The Journal of Clinical Investigation, Vol 132, Iss 22 (2022)
Prevalent copy number alteration is the most prominent genetic characteristic associated with ovarian cancer (OV) development, but its role in immune evasion has not been fully elucidated. In this study, we identified RAD21, a key component of the co
Externí odkaz:
https://doaj.org/article/d1d685a0f6e94ed4ad24a9147d62ada6
Autor:
Yuxiang Ma, Xin Zhao, Xi Chen, Xinxin Huang, Qingguang Lin, Yuehao Lin, Salvatore J Salamone, Xinlan Zhou, Changzheng Wang, Weiting Liang, Hongyun Zhao, Kui Wu, Yunpeng Yang, Li Zhang
Publikováno v:
Clinical and Translational Medicine, Vol 11, Iss 4, Pp n/a-n/a (2021)
Externí odkaz:
https://doaj.org/article/90690dfad45e4a1c88f0d67e8b93e143
Autor:
Peiyao Lu, Weiting Liang, Jiahao Li, Yanming Hong, Zhuojia Chen, Tao Liu, Pei Dong, Hongbing Huang, Tiantian Zhang, Jie Jiang
Publikováno v:
Frontiers in Pharmacology, Vol 11 (2020)
BackgroundCompared with the standard of care with sunitinib, avelumab plus axitinib can increase progression-free survival in the first-line of advanced renal cell carcinoma (RCC), but the economic effect of the treatment is unknown. The purpose of t
Externí odkaz:
https://doaj.org/article/d1212dd3b3464752865f599beeb11813